The U.S. Agency for International Development (USAID) submits this report pursuant to Section 7019(e) of the Department of State, Foreign Operations, and Related Programs Appropriations Act, 2024 (Division F, Public Law 118-47, Senate Report 118-71 and House Report 118-46, which state:
Senate Report 118-71: Not later than 60 days after the date of enactment of the act, the USAID Administrator shall update the report required under this heading in Senate Report 116–126 on USAID’s health-related research and development strategy. Such report shall include detail on USAID’s research and development of antibiotics.
Senate Report 116-126: The Committee recognizes USAID’s role in health-related research and supports continued investments in new global health technologies across each of USAID’s health related programs to address longstanding and emerging global health challenges. Not later than 60 days after enactment of the act, the USAID Administrator shall submit the annual report to the appropriate congressional committees on USAID’s health-related research and development strategy, which shall include: (1) specific health product development goals, including timelines for product development; (2) details about ongoing and planned investments in drugs, vaccines, diagnostics, and devices, including collaboration with other Federal agencies as well as private sector partners; (3) a detailed description of the mechanisms for collaboration and coordination in support of global health product development between Federal agencies; (4) an assessment of any critical gaps in product development for global health; and (5) recommendations for filling such gaps to ensure that U.S. investments in global health research are efficient, coordinated, and effective.
House Report 118-46: Antibiotics.—The Committee directs the Administrator of USAID to submit a report not later than 180 days after the date of enactment of this Act detailing research and development of antibiotics to be used in developing countries.
